Disease · MONDO_0024477
liver and intrahepatic bile duct neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. liver and intrahepatic bile duct neoplasm. Diseases, record MONDO_0024477. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024477
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
epithelial hepatic and intrahepatic bile duct neoplasm, hepatic and intrahepatic bile duct neoplasm, liver and intrahepatic bile duct epithelial neoplasm, liver neoplasm, liver neoplasm (disease), liver tumor, liver tumour, neoplasm of liver, tumor of liver, tumour of liver
- Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GADOXETATE DISODIUM | CHEMBL2103740 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESKETAMINE | CHEMBL395091 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
Targets17
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| BRAF | Serine/threonine-protein kinase B-raf | 1 | Serine/threonine-protein kinase B-raf inhibitor | Phase 3 | https://conductscience.org/library/genes/673 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 3 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 1/2 | https://conductscience.org/library/genes/116443 | Drugs and targets |
1 to 10 of 17
See all 17 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00492752 | A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Phase 3 | 226 | 2011-01-13 | Carcinoma, Hepatocellular | SORAFENIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02181075 | Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours | Phase 1 | 10 | 2019-06-24 | Liver Tumour | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov |
| NCT07034950 | Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation | Phase 1/2 | 79 | Hepatic Neoplasm, Hepatic Cancer | ESKETAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00093444 | Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | Phase 1 | 30 | Liver Cancer, Metastatic Cancer | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to ThermoDox (LTLD) | 3 of 6 | 4 of 4 | 10 | NCT02181075 | Trial comparisons |
Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Patients With Significant (Grade 3-5) Adverse Event(s) Deemed Related to FUS Procedure | 0 of 6 | 0 of 4 | 10 | NCT02181075 | Trial comparisons |
| Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): deaths from any cause | 0 of 6 | 0 of 4 | 10 | NCT02181075 | Trial comparisons |
Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Patients Demonstrating >Two-fold Increase in the Amount of Intratumoural Doxorubicin Before and After Focused Ultrasound | 4 of 6 | 3 of 4 | 10 | NCT02181075 | Trial comparisons |
| Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): serious adverse events | 3 of 6 | 3 of 4 | 10 | NCT02181075 | Trial comparisons |
| Part I (Patients Enrolled Between March 2015-April 2017) vs Part II (Patients Enrolled Between June 2016-Feb 2017): Persistence of Cell Viability Stain Post-LTLD+FUS | 5 of 5 | 3 of 4 | 9 | NCT02181075 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024477
GET https://conductscience.org/api/diseases/v1/MONDO_0024477/drugs